18.02
price up icon3.21%   0.56
after-market After Hours: 17.99 -0.03 -0.17%
loading
Teva Pharmaceutical Industries Ltd Adr stock is traded at $18.02, with a volume of 6.07M. It is up +3.21% in the last 24 hours and down -4.50% over the past month. Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
See More
Previous Close:
$17.46
Open:
$17.61
24h Volume:
6.07M
Relative Volume:
0.74
Market Cap:
$20.42B
Revenue:
$16.29B
Net Income/Loss:
$-476.00M
P/E Ratio:
-9.01
EPS:
-2
Net Cash Flow:
$679.00M
1W Performance:
+1.69%
1M Performance:
-4.50%
6M Performance:
+27.71%
1Y Performance:
+76.67%
1-Day Range:
Value
$17.59
$18.07
1-Week Range:
Value
$17.34
$18.07
52-Week Range:
Value
$8.055
$19.08

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile

Name
Name
Teva Pharmaceutical Industries Ltd Adr
Name
Phone
972 (3) 914-8213
Name
Address
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Name
Employee
37,851
Name
Twitter
@TevaUSA
Name
Next Earnings Date
2024-07-31
Name
Latest SEC Filings
Name
TEVA's Discussions on Twitter

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-12-24 Upgrade Piper Sandler Neutral → Overweight
Jan-23-24 Upgrade Jefferies Hold → Buy
Jan-03-24 Upgrade Piper Sandler Underweight → Neutral
Dec-18-23 Initiated HSBC Securities Buy
Nov-27-23 Upgrade UBS Neutral → Buy
Jul-06-23 Upgrade UBS Sell → Neutral
May-25-23 Initiated Morgan Stanley Equal-Weight
May-18-23 Upgrade Evercore ISI In-line → Outperform
Jan-19-23 Downgrade Jefferies Buy → Hold
Nov-14-22 Downgrade JP Morgan Neutral → Underweight
Nov-04-22 Downgrade UBS Neutral → Sell
Oct-21-22 Resumed Jefferies Buy
Aug-05-22 Upgrade BofA Securities Neutral → Buy
Jun-14-22 Resumed UBS Neutral
May-17-22 Upgrade BofA Securities Underperform → Neutral
May-04-22 Downgrade Piper Sandler Neutral → Underweight
Apr-05-22 Upgrade Barclays Equal Weight → Overweight
Mar-25-22 Upgrade Bernstein Mkt Perform → Outperform
Jan-27-22 Downgrade Argus Buy → Hold
Oct-28-21 Downgrade Raymond James Outperform → Mkt Perform
May-04-21 Downgrade UBS Buy → Neutral
Apr-07-21 Resumed RBC Capital Mkts Sector Perform
Nov-25-20 Initiated Oppenheimer Perform
Aug-06-20 Upgrade Barclays Underweight → Equal Weight
Jul-27-20 Resumed Goldman Neutral
Jun-01-20 Upgrade SunTrust Hold → Buy
Apr-24-20 Resumed Citigroup Neutral
Apr-06-20 Upgrade UBS Neutral → Buy
Feb-24-20 Downgrade Edward Jones Hold → Sell
Nov-12-19 Upgrade JP Morgan Underweight → Neutral
Oct-17-19 Upgrade Gabelli & Co Hold → Buy
Aug-07-19 Downgrade Evercore ISI Outperform → In-line
Jul-19-19 Initiated Wolfe Research Peer Perform
Jul-15-19 Downgrade Morgan Stanley Equal-Weight → Underweight
Jul-10-19 Resumed Credit Suisse Neutral
Jul-05-19 Upgrade Argus Hold → Buy
Jun-11-19 Initiated Barclays Underweight
Jun-03-19 Upgrade Oppenheimer Perform → Outperform
May-30-19 Downgrade BofA/Merrill Buy → Underperform
May-28-19 Downgrade UBS Buy → Neutral
Mar-20-19 Initiated SunTrust Hold
Mar-07-19 Resumed UBS Buy
View All

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Latest News

pulisher
Sep 27, 2024

Teva- Pharmaceutical Industries Ltd. ADR (TEVA): Worth A Small Bite At $17.54 - Stocks Register

Sep 27, 2024
pulisher
Sep 26, 2024

How will Teva- Pharmaceutical Industries Ltd. ADR’s (TEVA) earnings compare to estimates this quarter? - US Post News

Sep 26, 2024
pulisher
Sep 26, 2024

Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Shares Jump Approximately 70.34% Over the Year - Knox Daily

Sep 26, 2024
pulisher
Sep 24, 2024

Before You Invest, Make Sure You Check This New Oriental Education & Technology Group Inc. ADR (NYSE: EDU) Analysis – Stocks Register - Stocks Register

Sep 24, 2024
pulisher
Sep 24, 2024

TEVA’s Market Flip-Flop: Exploring the Volatility of 2023 Performance - The InvestChronicle

Sep 24, 2024
pulisher
Sep 24, 2024

Does Walmart Inc (NYSE: WMT) Still Need To Convince Analysts? - Stocks Register

Sep 24, 2024
pulisher
Sep 24, 2024

When Would Be The Best Time To Buy UiPath Inc (NYSE: PATH) Stock? - Stocks Register

Sep 24, 2024
pulisher
Sep 24, 2024

Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Stock trading around $17.72 per share: What’s Next? - The DBT News

Sep 24, 2024
pulisher
Sep 23, 2024

Checking in on Teva- Pharmaceutical Industries Ltd. ADR (TEVA) after recent insiders movement - Knox Daily

Sep 23, 2024
pulisher
Sep 21, 2024

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY (risperidone) Extended-Release Injectable Suspension from Perseris (RBP-7000) - wallstreet:online

Sep 21, 2024
pulisher
Sep 21, 2024

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia - GlobeNewswire Inc.

Sep 21, 2024
pulisher
Sep 21, 2024

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000) - GlobeNewswire Inc.

Sep 21, 2024
pulisher
Sep 19, 2024

DLTR Shares Experience Surge in Value - Knox Daily

Sep 19, 2024
pulisher
Sep 19, 2024

A company insider recently sold 708 shares of NAPCO Security Technologies Inc [NSSC]. Should You Sale? - Knox Daily

Sep 19, 2024
pulisher
Sep 19, 2024

Views of Wall Street’s Leading Experts on Teva- Pharmaceutical Industries Ltd. ADR - SETE News

Sep 19, 2024
pulisher
Sep 17, 2024

Keeping an Eye on Teva- Pharmaceutical Industries Ltd. ADR (TEVA) After Insider Trading Activity - Knox Daily

Sep 17, 2024
pulisher
Sep 16, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Sep 16, 2024
pulisher
Sep 16, 2024

Weekly Upgrades and Downgrades - MSN

Sep 16, 2024
pulisher
Sep 13, 2024

TEVA Shares Experience Surge in Value - Knox Daily

Sep 13, 2024
pulisher
Sep 12, 2024

Does Teva- Pharmaceutical Industries Ltd. ADR (TEVA) offer a good opportunity for investors? - SETE News

Sep 12, 2024
pulisher
Sep 12, 2024

Global Buccal Drug Delivery Systems Market Research 2024-2030 Featuring Johnson & Johnson, Pfizer, Sanofi, Novartis, Bayer, Teva Pharmaceuticals, AbbVie, Cipla, and Haleon - GlobeNewswire Inc.

Sep 12, 2024
pulisher
Sep 11, 2024

How analysts predict Teva- Pharmaceutical Industries Ltd. ADR (TEVA) will perform this quarter? - US Post News

Sep 11, 2024
pulisher
Sep 10, 2024

Argus analysts upgrades a Buy rating for Teva- Pharmaceutical Industries Ltd. ADR (TEVA) - Knox Daily

Sep 10, 2024
pulisher
Sep 10, 2024

Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies - Benzinga

Sep 10, 2024
pulisher
Sep 10, 2024

Teva- Pharmaceutical Industries Ltd. ADR Inc. (TEVA) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle

Sep 10, 2024
pulisher
Sep 06, 2024

JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability - Benzinga

Sep 06, 2024
pulisher
Sep 06, 2024

What will the future hold for Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) stock? - US Post News

Sep 06, 2024
pulisher
Sep 06, 2024

Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production - Benzinga

Sep 06, 2024
pulisher
Sep 06, 2024

Insider Selling: Daniell Richard, Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Exec. VP, European Commercial divested 98,943 shares – Knox Daily - Knox Daily

Sep 06, 2024
pulisher
Sep 05, 2024

insider CHURAY DANIEL J sale 16,975 shares of MRC Global Inc [MRC] - Knox Daily

Sep 05, 2024
pulisher
Sep 05, 2024

Pseudarthrosis Treatment Market is Projected to Reach $1.37 Billion at a CAGR 4.6% by 2034 | Fact.MR Report - GlobeNewswire Inc.

Sep 05, 2024
pulisher
Sep 03, 2024

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: Uncovering 52-Week Market Trends - The InvestChronicle

Sep 03, 2024
pulisher
Sep 03, 2024

Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Daniell Richard sells 98,943 Shares for $1.71 million - Knox Daily

Sep 03, 2024
pulisher
Sep 03, 2024

Tardive Dyskinesia (TD) Market Research 2024: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access - GlobeNewswire Inc.

Sep 03, 2024
pulisher
Sep 02, 2024

Liver Fibrosis Market Is Expected to Reach USD 43.98 Billion By 2030 - GlobeNewswire Inc.

Sep 02, 2024
pulisher
Aug 30, 2024

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) expanding its growth trajectory ahead - SETE News

Aug 30, 2024
pulisher
Aug 29, 2024

Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Records 200-Day SMA of $13.98 - Knox Daily

Aug 29, 2024
pulisher
Aug 29, 2024

Respiratory Drugs - GlobeNewswire Inc.

Aug 29, 2024
pulisher
Aug 28, 2024

For Teva- Pharmaceutical Industries Ltd. ADR [TEVA], Analyst sees a rise to $20. What next? - The DBT News

Aug 28, 2024
pulisher
Aug 28, 2024

Understanding TEVA stock ratios for better investment decisions - US Post News

Aug 28, 2024
pulisher
Aug 27, 2024

TEVA stock rated a Buy by Argus - Knox Daily

Aug 27, 2024
pulisher
Aug 27, 2024

Teva: Simlandi to See Share Gains in a Growing Humira Biosimilar Market Thanks to Formulary Update - Morningstar

Aug 27, 2024
pulisher
Aug 27, 2024

Pancreatic Cancer Treatment Market Size Worth USD 10.53 Billion by 2032 Driven by Rising Prevalence of Obesity, Smoking, and Alcohol Consumption | Research by SNS Insider - GlobeNewswire Inc.

Aug 27, 2024
pulisher
Aug 27, 2024

Teva- Pharmaceutical Industries Ltd. ADR’s Banking’s 100-Day Moving Average at 16.15: Will the Stock Break Through? - The InvestChronicle

Aug 27, 2024
pulisher
Aug 27, 2024

Premature Ejaculation Treatment Business Research Report 2024 Featuring Absorption Pharma, Allergan, AstraZeneca, Bayer, Eli Lilly and Co, GSK, Innovus, Merck, Pfizer, and Teva - GlobeNewswire Inc.

Aug 27, 2024
pulisher
Aug 26, 2024

Multiple Sclerosis (MS) Diagnosis and Treatment Market Size to Reach USD 30.28 Bn by 2032 - GlobeNewswire Inc.

Aug 26, 2024
pulisher
Aug 25, 2024

Global Acetaminophen-Opioid Combination Market Growth Accelerating Due to an Impressive USD 4,522.6 Million by 2034 Increased Usage in Cancer-Related Pain: Future Market Insights - GlobeNewswire Inc.

Aug 25, 2024
pulisher
Aug 25, 2024

Is SoundHound AI Stock a Buy Now? - The Motley Fool

Aug 25, 2024
pulisher
Aug 23, 2024

Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Shares Jump Approximately 88.62% Over the Year - Knox Daily

Aug 23, 2024
pulisher
Aug 23, 2024

Cancer Cachexia Market Forecasted to Reach $3.14 Billion by 2028 with a CAGR of 6.2% - GlobeNewswire Inc.

Aug 23, 2024
pulisher
Aug 23, 2024

Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - GlobeNewswire Inc.

Aug 23, 2024

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$11.61
price up icon 0.52%
drug_manufacturers_specialty_generic RDY
$79.45
price down icon 0.28%
$115.22
price up icon 0.14%
$60.57
price up icon 0.40%
$73.17
price down icon 0.18%
Cap:     |  Volume (24h):